Sebastien Maloveste, Ph.D.   |   Senior Vice President, Business Development

Dr. Maloveste was Director, Business Development at GenVec which he joined in 2015 as Associate Director, Business Development and worked closely with the senior management team in establishing business interactions with potential strategic partners. Dr. Maloveste participated in discussions leading to the acquisition of GenVec by Intrexon. Prior to joining GenVec, Dr. Maloveste held various position of increasing responsibilities at Amplimmune (now MedImmune/AstraZeneca), including Associate Director, Business Development and strategic alliance and project management. Dr. Maloveste received his Ph.D. in Immunology from the Université de la Méditerranée in Marseille, France. He performed postdoctoral research on immunology related to HIV vaccine at the National Institute of Allergies and Infectious Diseases, National Institutes of Health, and then at the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research. During his scientific career, Dr. Maloveste has published in peer-review journals, filed patent applications, and successfully obtained grant funding.

• Michael Richman President & CEO • Timothy Mayer, Ph.D. COO • Steven P. Cobourn, CPA CFO • Sol Langermann, Ph.D. CSO • Kevin Shaw General Counsel • Sourav Kundu, Ph.D. Senior Vice President, Development & Manufacturing • Udayan Guha, M.D., Ph.D. Senior Vice President, Clinical & Translational Development • Sebastien Maloveste, Ph.D. Senior Vice President, Business Development • Dallas Flies, Ph.D. Vice President, Discovery Research • Yvon Joseph Vice President, Quality Assurance